No Data
No Data
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
Market Rally at Risk as Tariffs Damage Spreads. -2-
Morgan Stanley Lifts Price Target on Pfizer to $32 From $31, Keeps Equalweight Rating
Express News | Pfizer : Leerink Partners Cuts Target Price to $26 From $28
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Pfizer's Mixed Q1 Results and Uncertain Long-Term Prospects Justify Hold Rating